Brief: Alkermes Announces FDA Approval Of Lybalvi For The Treatment Of Schizophrenia And Bipolar I Disorder
01/06/2021 14:24
June 1 (Reuters) - Alkermes Plc ALKS.O :
* ALKERMES ANNOUNCES FDA APPROVAL OF LYBALVI™ FOR THE
TREATMENT OF
SCHIZOPHRENIA AND BIPOLAR I DISORDER
* ALKERMES PLC - COMMERCIAL LAUNCH PLANNED FOR Q4 2021
* ALKERMES PLC - NEW ORAL MEDICATION OFFERS ESTABLISHED
ANTIPSYCHOTIC EFFICACY OF OLANZAPINE WITH LESS WEIGHT GAIN
Source text for Eikon: ID:nPn5phZCra
Further company coverage: ALKS.O
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Alkermes
See all newsBrief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
Brief: Alkermes Announces Effectiveness Of Mural Oncology Form 10 Registration Statement
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes Q3 Net Income USD 47.8 Million